Fundraising FoxEdenRoc Sciences
Worcester, US · Founded 2016 · Delaware LLC · 1 known investors
Find your way into EdenRoc Sciences
Sign up to see every warm intro you have to EdenRoc Sciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the EdenRoc Sciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
EdenRoc Sciences is a life sciences holding company that founds and funds subsidiary biotechnology companies addressing diseases of aging, with assets spanning genomic detection, clinical-stage pharmaceuticals, forensics, and biologic-based consumer products. Its subsidiaries operate autonomously while sharing board oversight and centralized business functions, and its work spans diagnostics and therapeutics across biotech and healthcare markets.
Founders & leadership
CW
Christopher WibblemanExecutive
ME
Mathew EasterdayExecutive
CM
Christopher McDonielExecutiveChristopher McDoniel leads fundraising, investor relations, and finance functions for EdenRoc Sciences and its portfolio companies. He previously worked in public accounting focusing on mergers and acquisitions, partnership taxation, and high-net-worth individual planning, and served as tax manager during the General Motors bankruptcy restructuring.
DS
David SinclairNamed on SEC filing
Board
JT
J. Taylor CrandallBoard director
TD
Todd DickinsonBoard director
JA
Jason AndersonBoard director
CB
Carlos BustamanteBoard director
EG
Ed GreenBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$219.9M disclosed across 10 rounds · 2016–2024
▶$2.8MraisedNov 2024 · 3 investors · BiotechnologyRule 506(b)
▶$2.8MraisedNov 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward SchulakExecutive Officer, Director
- Todd DickinsonDirector
- Christopher WibblemanDirector
- J. Taylor CrandallDirector
- Christopher McDonielExecutive Officer
- Mathew EasterdayExecutive Officer
- David SinclairDirector
- Offering amount
- $50M
- Amount sold
- $2.8M
- First sale
- Nov 2024
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$64.2MraisedJul 2024 · 50 investors · BiotechnologyRule 506(b)
▶$64.2MraisedJul 2024 · 50 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher WibblemanDirector
- David SinclairDirector
- J. Taylor CrandallDirector
- Mathew EasterdayExecutive Officer
- Christopher McDonielExecutive Officer
- Edward SchulakExecutive Officer, Director
- Todd DickinsonDirector
- Offering amount
- $64.2M
- Amount sold
- $64.2M
- First sale
- Jun 2022
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$35.9MraisedMay 2022 · 22 investors · BiotechnologyRule 506(b)
▶$35.9MraisedMay 2022 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mathew EasterdayExecutive Officer
- J.Taylor CrandallDirector
- Todd DickinsonDirector
- Edward SchulakExecutive Officer
- David SinclairDirector
- Christopher WibblemanDirector
- Offering amount
- $35.9M
- Amount sold
- $35.9M
- First sale
- May 2021
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$18MraisedNov 2021 · 10 investors · BiotechnologyRule 506(b)
▶$18MraisedNov 2021 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward SchulakExecutive Officer, Director
- Carlos BustamanteDirector
- Gregory LucierDirector
- Mathew EasterdayExecutive Officer
- J. Taylor CrandallDirector
- Todd DickinsonDirector
- David SinclairDirector
- Offering amount
- $18M
- Amount sold
- $18M
- First sale
- Aug 2020
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
▶$17.6MraisedJul 2020 · 11 investors · BiotechnologyRule 506(b)
▶$17.6MraisedJul 2020 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward SchulakExecutive Officer, Director
- Carlos BustamanteDirector
- Mathew EasterdayExecutive Officer
- Todd DickinsonDirector
- Jason AndersonDirector
- David SinclairDirector
- Amount sold
- $17.6M
- First sale
- Jan 2020
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
▶$8MraisedJul 2019 · 4 investors · BiotechnologyRule 506(b)
▶$8MraisedJul 2019 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edward SchulakExecutive Officer, Director
- Mathew EasterdayExecutive Officer
- Todd DickinsonDirector
- Jason AndersonDirector
- Carlos BustamanteDirector
- David SinclairDirector
- Offering amount
- $47.5M
- Amount sold
- $8M
- First sale
- Jul 2019
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
▶$13.5MraisedFeb 2019 · 4 investors · BiotechnologyRule 506(b)
▶$13.5MraisedFeb 2019 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mathew EasterdayExecutive Officer
- David SinclairDirector
- Jason AndersonDirector
- Carlos BustamanteDirector
- Todd DickinsonDirector
- Edward SchulakExecutive Officer, Director
- Offering amount
- $13.5M
- Amount sold
- $13.5M
- First sale
- Feb 2019
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
▶$15MraisedMar 2018 · 2 investors · BiotechnologyRule 506(b)
▶$15MraisedMar 2018 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carlos BustamanteDirector
- Mathew EasterdayExecutive Officer
- Jason AndersonDirector
- Edward SchulakExecutive Officer, Director
- Todd DickinsonDirector
- David SinclairDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Mar 2018
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Fortis Life SciencesFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Companies working in the same space as EdenRoc Sciences.
Frequently asked questions
- What does EdenRoc Sciences do?
- EdenRoc Sciences is a life sciences holding company that founds and funds subsidiary biotechnology companies addressing diseases of aging, with assets spanning genomic detection, clinical-stage pharmaceuticals, forensics, and biologic-based consumer products. Its subsidiaries operate autonomously while sharing board oversight and centralized business functions, and its work spans diagnostics and therapeutics across biotech and healthcare markets.
- Who are EdenRoc Sciences's investors?
- EdenRoc Sciences's investors include FOD Capital.
- How much funding has EdenRoc Sciences raised?
- EdenRoc Sciences has disclosed $219.9M raised across 10 rounds.
- Where is EdenRoc Sciences headquartered?
- EdenRoc Sciences is headquartered in Worcester, US.